Cutting edge: Defective NK cell activation in X-linked lymphoproliferative disease

Journal of Immunology

Volumn 165, Issue 7, 2000, Pages 3549-3553

  Benoit, L ^a   Wang, X ^a   Pabst, H F ^a   Dutz, J ^a   Tan, R ^a  

^a BC CHILDREN S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; LYMPHOCYTE RECEPTOR; SIGNALING LYMPHOCYTE ACTIVATION MOLECULE ASSOCIATED PROTEIN; SIGNALING LYMPHOCYTIC ACTIVATION MOLECULE ASSOCIATED PROTEIN 2B4; UNCLASSIFIED DRUG; CARRIER PROTEIN; CD244 PROTEIN, HUMAN; CD48 ANTIGEN; IMMUNOGLOBULIN RECEPTOR; IMMUNOLOGICAL ADJUVANT; LEUKOCYTE ANTIGEN; LIGAND; MEMBRANE PROTEIN; SH2D1A PROTEIN, HUMAN; SIGNAL PEPTIDE;

ARTICLE; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; LYMPHOKINE ACTIVATED KILLER CELL; LYMPHOPROLIFERATIVE DISEASE; MOLECULAR INTERACTION; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; X CHROMOSOME LINKED DISORDER; BIOSYNTHESIS; CELL CULTURE; CELL STRAIN K 562; CYTOTOXICITY; CYTOTOXICITY TEST; GENETIC LINKAGE; GENETICS; IMMUNE DEFICIENCY; IMMUNOLOGY; MALE; METABOLISM; MUTATION; PHYSIOLOGY; X CHROMOSOME;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, CD; CARRIER PROTEINS; CELLS, CULTURED; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; K562 CELLS; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; LIGANDS; LINKAGE (GENETICS); LYMPHOCYTE ACTIVATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MEMBRANE GLYCOPROTEINS; MUTATION; RECEPTORS, IMMUNOLOGIC; TUMOR CELLS, CULTURED; X CHROMOSOME;

EID: 0034294836     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.7.3549     Document Type: Article

References (37)

1. X-linked recessive progressive combined variable immunodeficiency (Duncan's disease)
2. X-linked lymphoproliferative disease: Twenty-five years after the discovery
3. Antibody responses to Epstein-Barr virus in families with the X-linked lymphoproliferative syndrome
4. X-linked lymphoproliferative syndrome: Abnormal antibody responses to bacteriophage φ X 174
5. Deficient natural killer cell activity in x-linked lymphoproliferative syndrome
6. Immune deficiency in the X-linked lymphoproliferative syndrome. I. Epstein-Barr virus-specific defects
7. Cell-mediated immunity to Epstein-Barr virus (EBV) and natural killer (NK)-cell activity in the X-linked lymphoproliferative syndrome
8. Defective natural killing activity but retention of lymphocyte-mediated antibody-dependent cellular cytotoxicity in patients with the X-linked lymphoproliferative syndrome
9. Cellular immune defects to Epstein-Barr virus-determined antigens in young males
10. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM
11. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene
12. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome
13. Cutting edge: Human 2B4, an activating NK cell receptor, recruits the protein tyrosine phosphatase SHP-2 and the adaptor signaling protein SAP
14. A novel function-associated molecule related to non-MHC-restricted cytotoxicity mediated by activated natural killer cells and T cells
15. Cloning and characterization of the 2B4 gene encoding a molecule associated with non-MHC-restricted killing mediated by activated natural killer cells and T cells
16. 2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48
17. Molecular characterization of a novel human natural killer cell receptor homologous to mouse 2B4
18. Crystal structures of the XLP protein SAP reveal a class of SH2 domains with extended, phosphotyrosine-independent sequence recognition
19. Novel mode of ligand binding by the SH2 domain of the human XLP disease gene product SAP/SH2D1A
20. Identification of the 2B4 molecule as a counter-receptor for CD48
21. + cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency
22. + killer cells
23. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells
24. Epstein-Barr virus-negative boys with non-Hodgkin lymphoma are mutated in the SH2D1A gene, as are patients with X-linked lymphoproliferative disease (XLP)
25. Identification of a novel signal transduction surface molecule on human cytotoxic lymphocytes
26. Activating interactions in human NK cell recognition: The role of 2B4-CD48
27. Growth factor requirements of childhood acute leukemia: Establishment of GM-CSF-dependent cell lines
28. + T cells in acute infectious mononucleosis
29. + T cells specific for EBV in healthy virus carriers
30. Adoptive cellular immunotherapy for EBV lymphoproliferative disease
31. Activated lymphocytes during acute Epstein-Barr virus infection
32. Inhibition of the in vitro outgrowth of Epstein-Barr virus-infected lymphocytes by TG lymphocytes
33. Natural killer cells inhibit outgrowth of autologous Epstein-Barr virus-infected B lymphocytes
34. Effective treatment of high-grade lymphoproliferative disorder after renal transplantation using autologous lymphocyte activated killer cell therapy
35. Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and negative lymphoproliferative disorders arising in organ transplant recipients
36. Function of CD48 and its regulation by Epstein-Barr virus